14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 86 days ( -3.92 % )
Last Price $2.65 0 %
High/ Low $2.65 - $2.65 0%
Chg 7 Days N/A $2.65 $2.65
Chg 30 Days N/A $2.65 $2.65
Chg 12 mos -15.61 % $3.14 $2.65
Trend - 3 mos -0.0246 % Width: 1.14 %
Trend - 12 mos 8.90 % Width: 192.72 %
Pred. range - 3 mos $2.63 - $2.66 -0.80 % - 0.330 %
Pred. range - 12 mos $1.38 - $4.04 -47.94 % - 52.39 %
Short MA avg 3 mos Sell Apr 01, 2024 - 57 days
Long MA avg 3 mos Sell May 07, 2024 - 31 days
Short/Long MA avg 3 mos Sell May 07, 2024 - 31 days
Short MA avg 12 mos Sell Apr 17, 2024 - 45 days
Long MA avg 12 mos Buy Nov 14, 2023 - 150 days
Short/Long MA avg 12 mos Buy Dec 05, 2023 - 136 days
Pivot Short Sell Mar 28, 2024 - 58 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Kinnate Biopharma Inc.

Kinnate Biopharma. Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growt... KNTE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT